|
Jun 26
|
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
|
|
Dec 19
|
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
|
|
Dec 6
|
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
|
|
Jul 13
|
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
|